196 related articles for article (PubMed ID: 22289032)
1. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.
Xue X; You S; Zhang Q; Wu Y; Zou GZ; Wang PC; Zhao YL; Xu Y; Jia L; Zhang X; Liang XJ
Mol Pharm; 2012 Mar; 9(3):634-44. PubMed ID: 22289032
[TBL] [Abstract][Full Text] [Related]
2. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.
Dhar S; Lippard SJ
Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22199-204. PubMed ID: 20007777
[TBL] [Abstract][Full Text] [Related]
3. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X
Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
[TBL] [Abstract][Full Text] [Related]
4. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.
Zajac J; Kostrhunova H; Novohradsky V; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2016 Mar; 156():89-97. PubMed ID: 26780576
[TBL] [Abstract][Full Text] [Related]
6. Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: a role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation.
Kumar A; Kant S; Singh SM
Toxicol Appl Pharmacol; 2013 Nov; 273(1):196-208. PubMed ID: 24051182
[TBL] [Abstract][Full Text] [Related]
7. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
8. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties.
Johnstone TC; Kulak N; Pridgen EM; Farokhzad OC; Langer R; Lippard SJ
ACS Nano; 2013 Jul; 7(7):5675-83. PubMed ID: 23697579
[TBL] [Abstract][Full Text] [Related]
10. Codominance of cisplatin resistance in somatic cell hybrids.
Ying YL; Shen DW; Liang XJ; Gottesman MM
J Cell Physiol; 2003 Jul; 196(1):63-9. PubMed ID: 12767041
[TBL] [Abstract][Full Text] [Related]
11. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
12. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.
Stockwin LH; Yu SX; Borgel S; Hancock C; Wolfe TL; Phillips LR; Hollingshead MG; Newton DL
Int J Cancer; 2010 Dec; 127(11):2510-9. PubMed ID: 20533281
[TBL] [Abstract][Full Text] [Related]
13. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
14. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum.
Liang XJ; Shen DW; Chen KG; Wincovitch SM; Garfield SH; Gottesman MM
J Cell Physiol; 2005 Mar; 202(3):635-41. PubMed ID: 15546142
[TBL] [Abstract][Full Text] [Related]
15. Targeting of two aspects of metabolism in breast cancer treatment.
Gang BP; Dilda PJ; Hogg PJ; Blackburn AC
Cancer Biol Ther; 2014; 15(11):1533-41. PubMed ID: 25482950
[TBL] [Abstract][Full Text] [Related]
16. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
17. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
18. A mitochondria-targeting hetero-binuclear Ir(iii)-Pt(ii) complex induces necrosis in cisplatin-resistant tumor cells.
Ouyang C; Chen L; Rees TW; Chen Y; Liu J; Ji L; Long J; Chao H
Chem Commun (Camb); 2018 Jun; 54(49):6268-6271. PubMed ID: 29850704
[TBL] [Abstract][Full Text] [Related]
19. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway.
Jelínková I; Šafaříková B; Vondálová Blanářová O; Skender B; Hofmanová J; Sova P; Moyer MP; Kozubík A; Kolář Z; Ehrmann J; Hyršlová Vaculová A
Biochem Pharmacol; 2014 Dec; 92(3):415-24. PubMed ID: 25285768
[TBL] [Abstract][Full Text] [Related]
20. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
